Clinical Trial Detail

NCT ID NCT03997968
Title A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Cyteir Therapeutics, Inc.
Indications

mantle cell lymphoma

ovarian cancer

diffuse large B-cell lymphoma

sarcoma

non-Hodgkin lymphoma

breast cancer

chronic lymphocytic leukemia

head and neck squamous cell carcinoma

pancreatic cancer

multiple myeloma

triple-receptor negative breast cancer

Therapies

CYT01B

Age Groups: senior adult

No variant requirements are available.